74697-68-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-chlorophenyl)butan-2-amine is used as a reagent for the preparation of antihypertensive β-adrenergic blocking agents. Its chemical structure allows it to be a key component in the synthesis of these medications, which are designed to treat high blood pressure and other cardiovascular conditions by blocking the action of adrenaline on certain receptors in the body.

Upstream product

• 3506-75-0 4-(4-chlorophenyl)butan-2-one 
• 104-88-1 4-chlorobenzaldehyde 
• 3160-40-5 4-(4-chlorophenyl)-3-buten-2-one 

Relevant academic research and scientific papers

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

β2-Agonists that bind to plasmalemmal β2-adrenoceptors causing cAMP accumulation are widely used as bronchodilators in chronic respiratory diseases. Here, we designed and synthesized a group of 8-hydroxyquinolin-2(1H)-one analogues and studied their β2-agonistic activities with a cellular cAMP assay. Compounds B05 and C08 were identified as potent (EC50 2-agonists among the compounds tested. They behaved as partial β2-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β2-agonists with potential applicability in chronic respiratory diseases.

Derivatives related to betaxolol with α- and β-adrenergic activities

The paper describes the synthesis and the pharmacological evaluation of some derivatives of betaxolol, all with an N-aralkylamine instead of the tertiobutylamine. These compounds have been tested for β1-adrenergic receptor antagonism on guinea pig atria, β2-adrenergic receptor antagonism on guinea pig trachea and α-adrenergic blocking activity on rat aorta. Compound U12 with a marked α-blocking activity and compound R8 with a β1/α ratio = 1 were selected for a haemodynamic study in the dog. The decrease in cardiac work and the diminution of total peripheral resistance exhibited by U12 are consistent with a dual α/β-blocking agent. Finally, structure-activity relationships are discussed.